<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02450773</url>
  </required_header>
  <id_info>
    <org_study_id>201501157</org_study_id>
    <nct_id>NCT02450773</nct_id>
  </id_info>
  <brief_title>Prevention of Severe Postpartum Hypertension</brief_title>
  <official_title>Furosemide for Prevention of Severe Postpartum Hypertension: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether postpartum administration of furosemide to
      women with antepartum hypertensive disorders (gestational hypertension, preeclampsia) or
      elevated blood pressure in the first 24 hours following delivery reduces severe postpartum
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite maternal morbidity</measure>
    <time_frame>0-6 weeks following delivery</time_frame>
    <description>Requiring antihypertensive medication at discharge, readmission for blood pressure, end-organ damage from hypertension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events associated with furosemide</measure>
    <time_frame>0-6 weeks following delivery</time_frame>
    <description>Hypokalemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events associated with furosemide</measure>
    <time_frame>0-6 weeks following delivery</time_frame>
    <description>hyperglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events associated with furosemide</measure>
    <time_frame>0-6 weeks following delivery</time_frame>
    <description>oliguria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events associated with furosemide</measure>
    <time_frame>0-6 weeks following delivery</time_frame>
    <description>hypotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events associated with furosemide</measure>
    <time_frame>0-6 weeks following delivery</time_frame>
    <description>elevated serum creatinine</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cardiovascular changes following delivery</measure>
    <time_frame>0-1 week following delivery</time_frame>
    <description>Maternal echocardiogram, renin, aldosterone, B-natriuretic peptide levels</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Furosemide/Potassium chloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg furosemide; 20 meq potassium chloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo #1, Placebo #2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>40 mg furosemide on postpartum day 1-6</description>
    <arm_group_label>Furosemide/Potassium chloride</arm_group_label>
    <other_name>Lasix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium chloride</intervention_name>
    <description>20 meq potassium chloride on postpartum day 1-6</description>
    <arm_group_label>Furosemide/Potassium chloride</arm_group_label>
    <other_name>KCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo #1</intervention_name>
    <description>Placebo (for furosemide)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo #2</intervention_name>
    <description>Placebo (for KCl)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women &gt; 18 years of age or emancipated minors

        Women undergoing vaginal or cesarean delivery at &gt; 23 weeks gestation with:

          -  Antepartum diagnosis of gestational hypertension

          -  Antepartum diagnosis of preeclampsia

          -  Antepartum diagnosis of preeclampsia with severe features

          -  Mild hypertension (&lt;150/100) in first 24 hours following delivery

        Exclusion Criteria:

          -  Chronic hypertension

          -  Allergy to furosemide

          -  Pre-existing hypokalemia (serum K &lt; 3.0 meq/L)

          -  Chronic kidney disease

          -  Serum Cr &gt; 1.1

          -  Inability to obtain informed consent

          -  Pre-existing diuretic use

          -  Oliguria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Methodius G. Tuuli, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shannon A Martin, RN</last_name>
    <phone>314-362-8523</phone>
    <email>martins@wudosis.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Martin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postpartum</keyword>
  <keyword>preeclampsia</keyword>
  <keyword>gestational hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

